COMPANY

OWP Pharmaceuticals

OWP offers three Starter Kits (Orange, Blue, and Green), each based on FDA-approved 5-week titration schedules, for patients initiating lamotrigine therapy. From company website Source · Oct 13, 2026

Keywords:

Location: Lisle, IL · source · Oct 15, 2026

Profile checked Oct 10, 2026

1FDA records (2 yrs)

Timeline

Sep 16, 2025 FDA FDA Original approval: SUBVENITE (lamotrigine) — NDA218879, Sep 16, 2025. Applicant at approval: OWP Pharmaceuticals, Inc. source ↗

FDA records (last 2 years)

Sep 16, 2025 FDA Original approval: SUBVENITE (lamotrigine) — NDA218879, Sep 16, 2025. Applicant at approval: OWP Pharmaceuticals, Inc. source ↗